Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $42.00 price target on the stock.
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Bitterroot Bio kickstarts Phase I trial for cardiovascular disease candidate [Yahoo! Finance]